Harbin Pharmaceutical Group Co., Ltd.

Equities

600664

CNE0000009T3

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-07-18 EDT 5-day change 1st Jan Change
3.3 CNY -0.30% Intraday chart for Harbin Pharmaceutical Group Co., Ltd. +10.00% -1.49%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Harbin Pharmaceutical to Upgrade Subsidiary's Production Line for 13 Million Yuan MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Roxatidine Hydrochloride for Injection of Harbin Pharma's Subsidiary Passes Drug Regulator's Evaluation MT
Harbin Pharmaceutical Group's Cefotiam Hydrochloride Selected for China's Centralized Procurement Bid MT
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Harbin Pharmaceutical Group Co., Ltd.(XSSC:600664) added to S&P Global BMI Index CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Jian´anxi Food Technology Co., Ltd announced that it expects to receive $20 million in funding from Harbin Pharmaceutical Group Co., Ltd. CI
Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Consumer Cos Up As NY Fed Survey Shows Consumer Optimism -- Consumer Roundup DJ
US senator asks for CFIUS review of GNC purchase by Chinese company RE
Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Chart Harbin Pharmaceutical Group Co., Ltd.
More charts
Harbin Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing, wholesale and retail of pharmaceutical. The Company is mainly engaged in two businesses. The pharmaceutical industry business is mainly engaged in the research, development and manufacturing of chemical raw materials, chemical preparations, biological preparations, traditional Chinese medicine and health care products. The pharmaceutical commercial business is mainly engaged in pharmaceutical commercial wholesale business and pharmaceutical commercial retail business. The Company's products mainly include zinc gluconate oral solution, calcium iron zinc oral solution, compound calcium gluconate oral solution, amoxicillin capsules and Shuanghuanglian oral solution. The Company's products are mainly used in digestive, respiratory, anti-infectious, cardiovascular and cerebrovascular and anti-tumor treatment fields.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 600664 Stock
  4. News Harbin Pharmaceutical Group Co., Ltd.
  5. Harbin Pharmaceutical to Upgrade Subsidiary's Production Line for 13 Million Yuan